Dr. Reddy’s Laboratories Announces the Launch of Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. Market

Dr. Reddy’s Laboratories Ltd announced that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal Allergy 24HR Tablets in the United States market as approved by the U.S. Food and Drug Administration (USFDA).

Levocetirizine Dihydrochloride Tablets USP, 5 mg is an over-the-counter antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing.

“This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,” says Milan Kalawadia, Vice President and Head, US Over-the-Counter and Speciality Rx businesses, Dr. Reddy’s Laboratories. “We look forward to collaborating with our customers to bring high-quality, affordable store brand alternatives to the market.”

The Xyzal Allergy 24HR Tablets brand had U.S. sales of approximately $71 million for the most recent twelve months ending in January 2018 according to IRI*.

Dr. Reddy’s Levocetirizine Dihydrochloride Tablets USP is available in 5 mg strength and in various consumer oriented package sizes.